Biotechnology

GeneTex Addresses GPCR Targets With Its Recombinant Monoclonal Antibody Production Platform

August 14, 2023 9:00 AM

IRVINE, CA / ACCESSWIRE / August 14, 2023 / GeneTex, a multinational antibody manufacturing company, is leveraging its recombinant monoclonal antibody production platform and augmented validation protocols to generate immunological reagents against high-value targets that have historically proven difficult to produce. G protein-coupled receptors (GPCRs), one of the most notoriously challenging groups, constitute the largest membrane protein...

Read more

Vaso Corporation Announces Financial Results for Second Quarter 2023

August 14, 2023 9:00 AM

Company reports continued growth in revenue and record profitability PLAINVIEW, NY / ACCESSWIRE / August 14, 2023 / Vaso Corporation ("Vaso") (OTCQB:VASO) today reported its operating results for the three months ended June 30, 2023. "For the quarter ended June 30, 2023, the Company recorded a total revenue of $20.4 million, representing a 5% growth from the same period last year, thanks to the great performance from all three of our business...

Read more

Lactiga Receives FDA 'Rare Pediatric Disease' Designation for Groundbreaking Mucosal Immunoglobulin Therapy for Common Variable Immunodeficiency Disease

August 14, 2023 8:00 AM

LCTG-001 on course to be the first FDA-approved biologic from human milk NEW BRUNSWICK, NJ / ACCESSWIRE / August 14, 2023 / Lactiga US, Inc., a visionary biotechnology company unlocking the therapeutic value of human milk antibodies, proudly announced today that the US Food and Drug Administration (USFDA) has granted "Rare Pediatric Disease" (RPD) designation for its biologic, LCTG-001, a mucosal antibody replacement therapy comprised of...

Read more

Serial Entrepreneur Dr. Darren Burke Unveils a Solution to End Crop Waste and Create New Revenue for Farms

August 11, 2023 9:00 AM

A game-changing start-up, "Future Foods," led by serial entrepreneur Dr. Darren Burke, is poised to revolutionize the agricultural landscape by addressing the longstanding challenge of crop wastage. HALIFAX, NS / ACCESSWIRE / August 11, 2023 / Future Foods, led by serial entrepreneur Dr. Darren Burke, is poised to revolutionize the agricultural landscape by addressing the longstanding challenge of crop wastage. The visionary company introduces a...

Read more

BillionToOne Publishes UNITY Fetal RhD and Fetal Antigen NIPT Clinical Validity Demonstrating >99.9% Accuracy

August 11, 2023 9:00 AM

In a clinical validation study published on Scientific Reports, UNITY RhD NIPT and Fetal antigen NIPT demonstrated 100% sensitivity, 100% specificity, 99.9% precision with 0.1% no-call rate across 3,921 NIPT assays. MENLO PARK, CA / ACCESSWIRE / August 11, 2023 / BillionToOne, experts in fetal DNA quantification, announced today that Scientific Reports published a study1 of the UNITY Fetal Antigen Noninvasive Prenatal Test (NIPT). The validation...

Read more

Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results

August 11, 2023 8:05 AM

- Company continues to execute on plan to advance DNase-based oncology program towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors FRAMINGHAM, MA / ACCESSWIRE / August 11, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat...

Read more

Imagene Launches ImageneOI Platform on Oracle Cloud Infrastructure to Democratize AI-Based Molecular Profiling in Oncology

August 11, 2023 8:00 AM

The ImageneOI rapid AI-based biomarker profiling platform significantly improves lung cancer patient outcomes, as demonstrated by a recently published case report. TEL AVIV, ISRAEL / ACCESSWIRE / August 11, 2023 / Imagene, an emerging leader in AI-based precision oncology, is proud to announce the launch of the ImageneOI platform on Oracle Cloud Infrastructure (OCI). The innovative platform, supported by proven clinical benefits, sets a new...

Read more

Ensysce Biosciences Reports Second Quarter 2023 Financial Results

August 11, 2023 8:00 AM

~ Progression Toward Full Phase 3 Evaluation of PF614 with Recently Announced IRB Approval of Key Study Protocol ~ SAN DIEGO, CA / ACCESSWIRE / August 11, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today reported financial results for the second quarter of 2023. Dr. Lynn Kirkpatrick, Chief Executive Officer of...

Read more

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

August 10, 2023 4:15 PM

- Raised an aggregate of $6.8 million in gross proceeds from two financings completed in 1H 2023 - - Received positive feedback on its End of Phase 2 meeting package from FDA in June 2023 - - Phase 3 STAR-1 study is projected to start enrolling patients in the 2H 2023 - SAN DIEGO, CA / ACCESSWIRE / August 10, 2023 / Dermata Therapeutics, Inc. (Nasdaq: DRMA; DRMAW) ("Dermata," or the "Company"), a clinical-stage biotechnology company focusing on...

Read more

Psycheceutical Announces Successful First Cohort Dosing; Moves to Dose Escalation in Phase I Trial of NeuroDirect Ketamine for PTSD

August 10, 2023 8:30 AM

Company's novel NeuroDirectTM topical ketamine formulation to treat PTSD shown to be safe and well-tolerated in first cohort of Phase I trial. MIAMI, FL / ACCESSWIRE / August 10, 2023 / Psycheceutical Bioscience, Inc. ("Psycheceutical" or the "Company") (OTC PINK:BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, today announced the completion of dosing of the first...

Read more

Edesa Biotech Reports Fiscal Third Quarter 2023 Results

August 9, 2023 4:15 PM

TORONTO, ON / ACCESSWIRE / August 9, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and nine months ended June 30, 2023 and provided an update on its business. During the fiscal third quarter, the company reported positive results from a university study of its monoclonal antibody, paridiprubart, against a...

Read more

Lexaria's DehydraTECH-Nicotine Faster than ZYN and on!

August 9, 2023 9:15 AM

DehydraTECH-Nicotine reaches maximum blood saturation levels faster than world-leading brands from Swedish Match and Altria in human study NIC-H22-1 Noteworthy superior subjective performance characteristics also observed KELOWNA, BC / ACCESSWIRE / August 9, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to report results from its 2023 human oral...

Read more

Oncocyte Regains Compliance With Nasdaq Listing Requirements

August 9, 2023 8:00 AM

IRVINE, CA / ACCESSWIRE / August 9, 2023 / Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it has received written notice from the Listing Qualifications Staff of the Nasdaq Stock Market ("Nasdaq") stating that the Company has regained compliance with the Nasdaq minimum bid price continued listing requirement and the matter is now closed. The Company was previously notified by Nasdaq on August 9, 2022...

Read more

CanariaBio Announces Enrollment Completion of Phase 2 Study of Oregovomab in Combination With Niraparib in the Treatment of Recurrent Ovarian Cancer

August 8, 2023 2:30 AM

SEOUL, SOUTH KOREA / ACCESSWIRE / August 8, 2023 / CanariaBio, a KOSDAQ-listed and a leading late-stage biotechnology company, announces the successful enrollment completion of a Phase 2 study of Oregovomab in combination with niraparib, GSK's poly (ADP-ribose) polymerase (PARP) inhibitor, for treatment of patients with platinum-sensitive recurrent ovarian cancer. This trial, known as FLORA-4 (NCT05335993), is being conducted by CanariaBio,...

Read more

EV Biologics Appoints Senior Investment Banker as Corporate Finance Director

August 7, 2023 8:00 AM

TAMPA, FL / ACCESSWIRE / August 7, 2023 / EV Biologics Corp, OTC PINK:YECO, today announced that it has appointed William Bossung as Corporate Finance Director. Mr. Bossung brings a wealth of experience as a long-time investment banker, with 5 decades of experience serving as a director and dealing with NYSE and NASDAQ companies. He is a regulatory expert with a deep understanding of public company finance and mainboard up listing procedures....

Read more

Lifeloc Reports Second Quarter 2023 Results

August 4, 2023 9:25 AM

WHEAT RIDGE, CO / ACCESSWIRE / August 4, 2023 / Lifeloc Technologies, Inc. (OTC PINK:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quarter ended June 30, 2023. Second Quarter Financial Highlights Lifeloc posted quarterly net revenue of $2.280 million in the second quarter of 2023, resulting in a quarterly net profit of $55 thousand, or $0.02 per...

Read more

Notice of Annual General Meeting in Biovica International AB

August 4, 2023 6:50 AM

UPPSALA, SWEDEN / ACCESSWIRE / August 4, 2023 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) The shareholders of Biovica International AB, reg. no. 556774-6150, (the "Company") are hereby invited to the annual general meeting to be held on Tuesday 5 September 2023, at 10.00 CET in Conference Hubben's premises on Dag Hammarskjölds Väg 38 in Uppsala. Right to attend the general meeting Shareholders wishing to attend the...

Read more

CAGE Bio Announces Positive Topline Results From its Double-Blind Phase 2 Study Evaluating an Ionic Liquid formulation of 1% Tofacitinib In Patients with Atopic Dermatitis

August 3, 2023 10:45 AM

SAN CARLOS, CA and FORT WORTH, TX / ACCESSWIRE / August 3, 2023 / CAGE Bio, Inc. (hereinafter "CAGE Bio") a biotechnology company focused on developing innovative drug therapies for localized treatment of immuno-dermatological disorders, today announced positive results from its randomized, vehicle controlled, phase 2 study evaluating the safety and efficacy of CGB-500, an ionic liquid formulation of 1% Tofacitinib, in patients with Atopic...

Read more

AppYea Announces Equity Financing Transaction to Accelerate Commercial Launch

August 3, 2023 9:20 AM

Transaction expected to streamline capital structure and ultimately result in the elimination of all Company debt GAN YAVNE, ISRAEL / ACCESSWIRE / August 3, 2023 / AppYea Inc. (OTC:APYP), a healthtech company focused on the development of accurate wearable monitoring solutions to treat sleep apnea and snoring, today announced the recent signing of an equity financing transaction with a group of strategic investors. The financing is expected to...

Read more

EV Biologics Hires Senior Chief Financial Officer

August 2, 2023 9:00 AM

TAMPA, FL / ACCESSWIRE / August 2, 2023 / EV Biologics Corp (OTC PINK:YECO) today announced that it has hired Monte Fisher as Chief Financial Officer. Mr. Fisher brings a wealth of experience as a long-time senior employee of Shell Oil, based in Houston, Texas where he held key leadership roles within Shell Finance. He is a corporate governance and compliance expert with a deep understanding of finance processes and risk controls. Mr. Fisher...

Read more